Continued preclinical investigation into how IDO1, and tryptophan catabolism more generally, contribute to tumor development in different settings will be critical to developing the more sophisticated contextual framework essential to informing future development of IDO1 inhibitors for cancer treatment. The gene discussed is IDO1; the disease is cancer.